Boston Scientific buys nVision Medical

NEC Member Boston Scientific recently announced its purchase of nVision medical, a California med-tech firm that’s developing a device to screen women for ovarian cancer. It was reported that Boston Scientific will pay $150 million upfront and another $125 million in later payments, totaling a $275 million purchase.

Boston Scientific sees large market potential of around $500 million per year for nVision’s devices, predicting that the market eventually could grow to $2 billion. The reason the device is valuable is that there has not previously been a  screening test for this particular form of cancer and that current testing methods yield false-positives leading to unnecessary surgery.

The deal marks Boston Scientific’s second cancer-related acquisition in recent weeks, having previously bought Minnesota’s NxThera which makes devices to treat enlarged prostates.

The New England Council congratulates Boston Scientific for its continued growth and looks forward to the continued development of this important cancer screening tool. Read more on Boston Business Journal.

img_side
mask_sidebar
Recently from the Blog

New Member ABBYY Provides Language Services to Businesses Worldwide

10/16/2018 | Read Post

Scientific Management Techniques Reports Higher Manufacturing Skill Assessment Scores in 2018

10/16/2018 | Read Post

In the News

NEC to Honor Gen. Joseph F. Dunford Jr., Vertex CEO Dr. Jeffrey Leiden, Veterans’ Advocate Travis Mills, Rep. Niki Tsongas

10/2/2018 | Read Press Release

NEC Releases Report on Economic Impact of REITs

09/20/2018 | Read Press Release